1.Study on the anticancer effect of apigenin on leukemia cells
Erdenezaya O ; Enkhkhishig O ; Egshiglen A ; Ulziisaikhan B ; Nomiungerel R ; Enkhmaa D ; Uugangerel E
Mongolian Journal of Health Sciences 2025;88(4):52-55
Background:
The study of small-molecule compounds with antitumor activity involves several crucial steps. These
include determining their selective effects on cancer cells, understanding the type of cell death they induce, identifying
the activated signaling pathways, pinpointing the target molecules, and elucidating the mechanisms of action. Among the
plant-derived compounds with anticancer properties, flavonoids are notable for their ease of isolation and their abundance
in food. Apigetrin, a representative flavonoid, is a secondary metabolite found in plants, and our previous study indicated
that its anticancer selectivity index was 13.1. However, the specific mechanism by which apigetrin inhibits leukemia cell
growth remains unclear.
Aim:
To study of the inhibitory action of apigenin on leukemia cell culture
Materials and Methods:
In this study, we evaluated the apoptosis of cells using flow cytometry and investigated the in
volvement of the caspase pathway through the use of pancaspase inhibitors to explore the effects of apigetrin on leukemia
cell growth.
Results:
After incubating leukemia RAW264.7 cells with 30 μM apigetrin for 24 and 48 hours, we did not detect any
apoptosis through Annexin V and PI staining by flow cytometry. We compared the number of viable cells using the MTT
assay after 24-hour treatment of apigetrin with or without pretreatment of Z-VAD, a pancaspase inhibitor, for 30 min
utes. The results indicated that the pancaspase inhibitor did not reduce the inhibitory effect of apigetrin on the growth of
RAW264.7 cells. In contrast, the positive control group, treated with doxorubicin—which induces apoptosis—showed
not only significant apoptosis but also a reduction of the pancaspase inhibitor on the cell growth inhibition. Therefore,
these data suggested that apigetrin likely has a cytostatic effect or inhibits the cell cycle rather than being cytotoxic. Future
research should focus on determining which stage of the cell cycle RAW264.7 cells treated with apigetrin are in, as well
as studying the signaling pathways involved in the cell cycle.
Conclusions
Apigetrin inhibits the proliferation of RAW264.7 leukemia cells in a caspase-independent and non-apoptotic
manner.
2. Results of a comparative study on Non-alcoholic fatty liver induced and microstructural fibrotic changes
Suvd M ; Badrakh M ; Enkhee O ; Onon B ; Gan-Erdene B ; Nomiungerel R ; Avirmed A ; Khongorzul B
Mongolian Journal of Health Sciences 2025;88(4):188-192
Background:
In recent years, the incidence of liver diseases due to complications of non-alcoholic fatty liver disease
(NAFLD) has shown a significant upward trend in Southeast Asian countries. NAFLD is a hepatic disorder characterized
by lipid accumulation in the microstructure of the liver in individuals who consume little to no alcohol. It is often associ
ated with insulin resistance and is diagnosed when steatosis affects more than 5% of hepatocytes histologically, or when
the fat signal intensity on MRI exceeds 5.6%, based on fat-to-water ratio measurements. In Mongolia, histological studies
using frozen liver sections with routine and special staining techniques are limited, highlighting the necessity of this study.
Aim:
To determine and compare the degree of steatosis and fibrosis in frozen liver tissue samples of patients with NAFLD
through histological analysis.
Materials and Methods:
This study was conducted at the the Department of Anatomy, School of Biomedicine and Bio
medical Research Institute of MNUMS in collaboration with the Second State Central Hospital. Ethical approval was
obtained from the Research Ethics Committee of MNUMS (Protocol No. 2024/3-06). All procedures adhered strictly to
laboratory biosafety protocols. Participants were selected among patients undergoing elective laparoscopic cholecystec
tomy, from whom informed consent was obtained. Based on inclusion criteria, five participants were grouped as follows:
healthy control (n=1), NAFLD without fibrosis (n=2), and NAFLD with fibrosis (n=2). Liver biopsies (approx. 1 cm in
size) were obtained intraoperatively, immediately deep-frozen in liquid nitrogen, and prepared for histological evaluation.
Results:
In patients with NAFLD compared to the healthy liver group, disruption of hepatocyte columnar architecture and
mild periportal lymphocytic infiltration were observed. Oil Red O staining revealed 34–66% micro- and macrovesicular
steatosis, corresponding to grade 2 steatosis. Masson’s trichrome staining showed no fibrotic changes in perivenular or
periportal areas (Ishak grade 0/4) at this stage. However, upon progression to grade 3 steatosis, early-stage fibrosis was
observed in both perivenular and periportal regions (Ishak grade 1/4). Further progression to stage 4 fibrosis was char
acterized by the development of connective tissue septa, although no significant changes in droplet size were observed.
Conclusions
1. Increasing stages of fibrosis are not directly influenced by the severity of hepatic steatosis in NAFLD.
2. Although the degree of steatosis increases, the absence of corresponding fibrotic changes in early stages indicates a
complex progression pattern of NAFLD requiring further investigation.